Additionally, Fang et al. [49] evaluated AQP4 polymorphisms in PD together with Positron Emission Tomography measures of beta-amyloid burden, sleep behavior, and CSF biomarkers and observed that AQP4 rs162009 may be a biomarker of cognitive decline in PD, possibly attributable to its role in changing neurofluid circulation. Here, AQP4 is linked to Parkinson disease.